(R)-Butaprost, free acid (CAS 215168-33-5)

(R)-Butaprost, free acid, known for its molecular structure, has been extensively investigated in scientific research for its potential applications in understanding prostaglandin signaling pathways and developing pharmacological tools for studying related biological processes. This compound, possessing a chiral center, specifically targets and activates prostaglandin E receptor 2 (EP2), a G protein-coupled receptor involved in various physiological and pathological processes, including inflammation, pain, and cancer progression. Through selective binding to EP2, (R)-Butaprost elicits downstream signaling cascades, such as the cyclic adenosine monophosphate (cAMP) pathway, leading to the modulation of cellular responses and gene expression. Researchers have utilized (R)-Butaprost as a pharmacological probe to explain the functional roles of EP2 in diverse biological contexts, including immune regulation, cardiovascular homeostasis, and neuronal signaling. Furthermore, this compound has been instrumental in deciphering the potential of EP2 modulation in preclinical studies, offering insights into its implications for the development of novel treatments for inflammatory disorders, cardiovascular diseases, and certain types of cancer. The research on (R)-Butaprost continues to advance our understanding of prostaglandin biology and may pave the way for the discovery of new interventions targeting EP2-mediated pathways.